Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7248155 | 0.87 | KMT2A (0.43) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL8773828 | 0.82 | MEN1 (0.43) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3576620 | 0.78 | KDM4E (0.53) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL6036163 | 0.71 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1MAPTIDO1 | |
| SCHEMBL24218942 | 0.71 | LMNA (0.52) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL27476004 | 0.71 | TTR (0.44) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL9031190 | 0.71 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2566903 | 0.71 | FUCA1 (0.43) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL13483414 | 0.70 | KMT2A (0.47) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL22430515 | 0.70 | HSD17B10 (0.51) | MEN1KMT2AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1490062-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-6903215-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1490062-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003082280-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | NR3C1, NR3C2, MC2R | MEN1 1089/4885KMT2A 4152/4885ALDH1A1 3583/4885 |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MEN1 926/4885KMT2A 4146/4885ALDH1A1 3426/4885 |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MEN1 1456/4885KMT2A 4388/4885ALDH1A1 2659/4885 |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | MEN1 804/4885KMT2A 4098/4885ALDH1A1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.